Idelalisib is an oral kinase inhibitor that is approved for use in combination with rituximab in relapsed or refractory chronic lymphocytic leukemia (CLL) and as monotherapy for relapsed follicular B cell, small lymphocytic lymphoma, and indolent non-Hodgkin lymphoma. Idelalisib is associated with a high rate of serum enzyme elevations during therapy and has been reported to cause clinically apparent acute liver injury that can be severe and even fatal.
Idelalisib is an orally bioavailable, small-molecule inhibitor of the delta isoform of the 110 kDa catalytic subunit of class I phosphoinositide-3 kinase (PI3K) with potential immunomodulating and antineoplastic activities. Idelalisib inhibits the production of the second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3), preventing the activation of the PI3K signaling pathway and inhibiting tumor cell proliferation, motility, and survival. Unlike other isoforms of PI3K, PI3K-delta is expressed primarily in hematopoietic lineages. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells.
Idelalisib is a member of the class of quinazolines that is 5-fluoro-3-phenylquinazolin-4-one in which the hydrogen at position 2 is replaced by a (1S)-1-(3H-purin-6-ylamino)propyl group. used for the treatment of refractory indolent non-Hodgkin’s lymphoma and relapsed chronic lymphocytic leukemia. It has a role as an antineoplastic agent, an apoptosis inducer, and an EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor. It is a member of purines, an organofluorine compound, a member of quinazolines, an aromatic amine, and a secondary amino compound.
Mechanism of Action
Idelalisib specifically inhibits P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. In contrast to the other class IA PI3Ks p110α and p110β, p110δ is principally expressed in leukocytes (white blood cells) and is important for the function of T cells, B cell, mast cells and neutrophils. By inhibiting this enzyme, idelalisib induces apoptosis of malignant cells and inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and type 4 signalling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone marrow. Treatment of lymphoma cells with idelalisib has been shown to result in inhibition of chemotaxis and adhesion, and reduced cell viability.
or
Idelalisib is an inhibitor of PI3Kdelta kinase, which is expressed in normal and malignant B-cells. Idelalisib induced apoptosis and inhibited proliferation in cell lines derived from malignant B-cells and in primary tumor cells. Idelalisib inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and the CXCR4 and CXCR5 signaling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone marrow. Treatment of lymphoma cells with idelalisib resulted in inhibition of chemotaxis and adhesion, and reduced cell viability.
Indications
- Idelalisib is indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies.
- Zydelig is indicated in combination with an anti‑CD20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (CLL): who have received at least one prior therapy, or as first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies.
- Zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (FL) that is refractory to two prior lines of treatment.
- Idelalisib is an oral kinase inhibitor that is approved for use in combination with rituximab in relapsed or refractory chronic lymphocytic leukemia (CLL) and as monotherapy for relapsed follicular B cell, small lymphocytic lymphoma and indolent non-Hodgkin lymphoma.
- Idelalisib is an antineoplastic kinase inhibitor used to treat chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL).
- Idelalisib is a second-line drug for patients whose chronic lymphocytic leukemia (CLL) has relapsed. Used in combination with rituximab,[rx] idelalisib is to be used in patients for whom rituximab alone would be considered appropriate therapy due to other existing medical conditions.[rx] It appears to be effective and leads to improvement of lymphadenopathy and splenomegaly. However, the lymphocyte counts take longer to decrease to normal levels with idelalisib. It is not recommended as a first-line treatment.[rx]
- It is also approved for the treatment of follicular B-cell non-Hodgkin lymphoma (FL) and relapsed small lymphocytic lymphoma (SLL), both in patients who have received at least two prior systemic therapies.[rx]
- In combination with rituximab, for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL) for whom rituximab alone would be considered appropriate therapy due to other co-morbidities. The treatment of patients with relapsed follicular B-cell non-Hodgkin lymphoma (FL) who have received at least 2 prior systemic therapies. The treatment of patients with relapsed small lymphocytic lymphoma (SLL) who have received at least 2 prior systemic therapies.
- Relapsed Chronic Lymphocytic Leukemia
- Relapsed Small Lymphocytic Lymphoma
- Relapsed follicular B-cell non-Hodgkin’s lymphoma
Use in Cancer
Idelalisib is approved to treat:
- Chronic lymphocytic leukemia (CLL) that has relapsed (come back). It is used with rituximab in patients who may be treated with rituximab alone due to other health problems.
Idelalisib is also being studied in the treatment of other types of cancer.
Contraindications
- a bad infection
- decreased blood platelets
- low levels of a type of white blood cell called neutrophils
- a type of inflammation of the lung called interstitial pneumonitis
- a hole in the intestine
- liver problems
- high amount of bilirubin in the blood
- diarrhea
- abnormal liver function tests
- pregnancy
- a patient who is producing milk and breastfeeding
- progressive multifocal leukoencephalopathy, a type of brain infection
Dosage
Strengths: 100 mg; 150 mg
Non-Hodgkin’s Lymphoma
- 150 mg orally 2 times a day until disease progression or unacceptable toxicity
- This drug can be taken with or without food.
- Tablets should be swallowed whole.
- If the patient misses a dose within 6 hours of the time it is usually taken, the patient should take the missed dose as soon as possible and resume the normal dosing schedule.
- If a patient misses a dose by more than 6 hours, the patient should not take the missed dose and simply resume the usual dosing schedule.
Chronic Lymphocytic Leukemia
- 150 mg orally 2 times a day until disease progression or unacceptable toxicity
- This drug can be taken with or without food.
- Tablets should be swallowed whole.
- If the patient misses a dose within 6 hours of the time it is usually taken, the patient should take the missed dose as soon as possible and resume the normal dosing schedule.
- If a patient misses a dose by more than 6 hours, the patient should not take the missed dose and simply resume the usual dosing schedule.
Lymphoma
- 150 mg orally 2 times a day until disease progression or unacceptable toxicity
- This drug can be taken with or without food.
- Tablets should be swallowed whole.
- If the patient misses a dose within 6 hours of the time it is usually taken, the patient should take the missed dose as soon as possible and resume the normal dosing schedule.
- If a patient misses a dose by more than 6 hours, the patient should not take the missed dose and simply resume the usual dosing schedule.
- In combination with rituximab, for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL) for whom rituximab alone would be considered appropriate therapy due to other co-morbidities.
- The treatment of patients with relapsed follicular B-cell non-Hodgkin lymphoma (FL) who have received at least 2 prior systemic therapies.
- The treatment of patients with relapsed small lymphocytic lymphoma (SLL) who have received at least 2 prior systemic therapies.
Liver Dose Adjustments
- AST and/or ALT greater than 3 to 5 times the upper limit of normal (3 to 5 x ULN): Maintain dose, monitor at least weekly until less than or equal to ULN.
- AST and/or ALT greater than 5 to 20 x ULN: Withhold therapy, monitor at least weekly until less than or equal to ULN, may resume at 100 mg twice a day.
- AST and/or ALT greater than 20 x ULN: Permanently discontinue therapy.
- Bilirubin greater than 1.5 to 3 x ULN: Maintain dose, monitor at least weekly until less than or equal to ULN.
- Bilirubin greater than 3 to 10 x ULN: Withhold therapy, monitor at least weekly until less than or equal to ULN, may resume at 100 mg twice a day.
- Bilirubin greater than 10 x ULN: Permanently discontinue therapy.
Dose Adjustments
Pneumonitis:
- Discontinue therapy in patients with any severity of symptomatic pneumonitis.
Diarrhea:
- If moderate diarrhea develops during therapy (increase of 4 to 6 stools per day over baseline), maintain dose and monitor at least weekly until resolved.
- If severe diarrhea develops during therapy (increase of 7 or more stools per day over baseline), withhold therapy and monitor at least weekly until resolved, then resume therapy at 100 mg twice a day.
- If life-threatening diarrhea develops during treatment, discontinue therapy permanently.
Neutropenia:
- ANC 1 to less than 1.5 Gi/L: Maintain dose.
- ANC 0.5 to less than 1 Gi/L: Maintain dose and monitor ANC at least weeky.
- ANC less than 0.5: interrupt therapy and monitor at least weekly until ANC is 0.5 Gi/L or greater, then resume therapy at 100 mg twice a day.
Thrombocytopenia:
- Platelets 50 to less than 75 Gi/L: Maintain dose.
- Platelets 25 to less than 50 Gi/L: Maintain dose and monitor platelet counts at least weekly.
- Platelets less than 25 Gi/L: Withhold therapy and monitor at least weekly; resume therapy at 100 mg twice a day when platelets are 25 Gi/L or greater.
Infections:
- Grade 3 or higher sepsis or pneumonia: Interrupt therapy until infection has resolved.
- Evidence of CMV infection or viremia: Interrupt therapy in patients with evidence of active CMV infection of any grade or viremia (positive PCR or antigen test) until the viremia has resolved. If therapy is resumed, monitor patients by PCR or antigen test for CMV reactivation at least monthly.
- Evidence of PJP infection: Interrupt therapy in patients with suspected PJP infection of any grade. Permanently discontinue therapy if PJP infection is confirmed.
Lymphocytosis:
- No dose modification is required for lymphocytosis, which has been observed in some patients taking this drug. This lymphocytosis is a pharmacodynamic effect and should not be considered progressive disease in the absence of other clinical findings.
FATAL AND SERIOUS TOXICITIES: HEPATIC, SEVERE DIARRHEA, COLITIS, PNEUMONITIS, INFECTIONS, and INTESTINAL PERFORATION:
- Fatal and/or serious hepatotoxicity occurred in 16% to 18% of patients. Monitor hepatic function prior to and during therapy. Interrupt therapy and then reduce or discontinue the drug as recommended.
- Fatal and/or serious and severe diarrhea or colitis occurred in 14% to 20% of patients. Monitor for development of severe diarrhea or colitis. Interrupt therapy and then reduce or discontinue the drug as recommended.
- Fatal and/or serious pneumonitis occurred in 4% of patients. Monitor for pulmonary symptoms and bilateral interstitial infiltrates. Interrupt therapy and then reduce or discontinue the drug as recommended.
- Fatal and/or serious infections occurred in 21% to 48% of patients. Monitor for infection. Interrupt therapy if infection is suspected.
- Fatal and serious intestinal perforation can occur. Discontinue therapy for intestinal perforation.
Administration advice:
- Take with or without food.
- Tablets should be swallowed whole.
Side Effects
The Most Common
- headache
- difficulty falling asleep or staying asleep
- decreased appetite
- increased thirst
- heartburn
- joint pain
- night sweats
- lack of energy
- swelling of the hands, feet, ankles, or lower legs
- red, itching, peeling, or blistering skin
- painful sores or ulcers on your skin, lips, or in your mouth
- difficulty swallowing or breathing; swelling of the face, lips, or throat; hives; itching
- Bloating or swelling of the face, arms, hands, lower legs, or feet
- decreased appetite
- difficulty with moving
- muscle pain or stiffness
- night sweats
- pain in the joints
- rapid weight gain
- tingling of the hands or feet
- trouble sleeping
- unusual weight gain or loss
More common
- Black, tarry stools
- body aches or pain
- chest tightness
- chills
- clay colored stools
- confusion
- cough
- cough producing mucus
- dark urine
- decreased appetite
- difficulty with breathing
- dizziness
- ear congestion
- fainting
- fast heartbeat
- fever
- headache
- itching or skin rash
- lightheadedness
- loss of appetite
- loss of voice
- lower back or side pain
- nausea and vomiting
- pain
- pain or tenderness around the eyes and cheekbones
- painful or difficult urination
- pale skin
- rapid, shallow breathing
- sneezing
- sore throat
- stomach cramps, pain, or tenderness
- stuffy or runny nose
- swelling of the feet or lower legs
- trouble breathing
- ulcers, sores, or white spots in the mouth
- unusual bleeding or bruising
- unusual tiredness or weakness
- watery or bloody diarrhea
- yellow eyes or skin
Rare
- Bladder pain
- bloody or cloudy urine
- difficult, burning, or painful urination
- frequent urge to urinate
- lower back or side pain
- Blistering, peeling, or loosening of the skin
- chest pain
- cracks in the skin
- difficulty with swallowing
- general feeling of discomfort or illness
- heartburn
- hives
- indigestion
- joint or muscle pain
- loss of heat from the body
- puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
- red skin lesions, often with a purple center
- red, irritated eyes
- red, swollen skin
- scaly skin
- severe abdominal or stomach pain, cramping, or burning
- thickening of bronchial secretions
- vomiting of material that looks like coffee grounds, severe and continuing
Drug Interactions
| DRUG | INTERACTION |
|---|---|
| Abametapir | The serum concentration of Idelalisib can be increased when it is combined with Abametapir. |
| Abatacept | The metabolism of Idelalisib can be increased when combined with Abatacept. |
| Abemaciclib | The metabolism of Abemaciclib can be decreased when combined with Idelalisib. |
| Abrocitinib | The serum concentration of Idelalisib can be increased when it is combined with Abrocitinib. |
| Acalabrutinib | The metabolism of Idelalisib can be decreased when combined with Acalabrutinib. |
| Acenocoumarol | The serum concentration of Acenocoumarol can be increased when it is combined with Idelalisib. |
| Acetaminophen | The metabolism of Idelalisib can be increased when combined with Acetaminophen. |
| Acetazolamide | The metabolism of Idelalisib can be decreased when combined with Acetazolamide. |
| Adalimumab | The metabolism of Idelalisib can be increased when combined with Adalimumab. |
| Adenovirus type | The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Idelalisib. |
| Afatinib | Afatinib may decrease the excretion rate of Idelalisib which could result in a higher serum level. |
| Albendazole | The metabolism of Idelalisib can be decreased when combined with Albendazole. |
| Aldesleukin | The metabolism of Idelalisib can be decreased when combined with Aldesleukin. |
| Alectinib | The metabolism of Alectinib can be decreased when combined with Idelalisib. |
| Alefacept | The risk or severity of adverse effects can be increased when Alefacept is combined with Idelalisib. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Idelalisib. |
| Alfuzosin | The metabolism of Alfuzosin can be decreased when combined with Idelalisib. |
| Allogeneic | The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Idelalisib. |
| Alpelisib | The metabolism of Idelalisib can be increased when combined with Alpelisib. |
| Alprazolam | The metabolism of Alprazolam can be decreased when combined with Idelalisib. |
| Altretamine | The risk or severity of adverse effects can be increased when Altretamine is combined with Idelalisib. |
| Ambrisentan | The serum concentration of Idelalisib can be increased when it is combined with Ambrisentan. |
| Aminoglutethimide | The metabolism of Idelalisib can be increased when combined with Aminoglutethimide. |
| Aminophylline | The metabolism of Aminophylline can be decreased when combined with Idelalisib. |
| Amiodarone | The metabolism of Idelalisib can be decreased when combined with Amiodarone. |
| Amobarbital | The metabolism of Idelalisib can be increased when combined with Amobarbital. |
| Amprenavir | The metabolism of Idelalisib can be decreased when combined with Amprenavir. |
| Amsacrine | The risk or severity of adverse effects can be increased when Amsacrine is combined with Idelalisib. |
| Anakinra | The metabolism of Idelalisib can be increased when combined with Anakinra. |
| Anifrolumab | The risk or severity of adverse effects can be increased when Idelalisib is combined with Anifrolumab. |
| Anthrax immune | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Idelalisib. |
| Anthrax vaccine | The risk or severity of infection can be increased when Anthrax vaccine is combined with Idelalisib. |
| Antilymphocyte | The risk or severity of adverse effects can be increased when Idelalisib is combined with Antilymphocyte immunoglobulin (horse). |
| Antithymocyte | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Idelalisib. |
| Apalutamide | The serum concentration of Idelalisib can be decreased when it is combined with Apalutamide. |
| Apixaban | The serum concentration of Idelalisib can be increased when it is combined with Apixaban. |
| Apremilast | The metabolism of Idelalisib can be increased when combined with Apremilast. |
| Aprepitant | The metabolism of Idelalisib can be decreased when combined with Aprepitant. |
| Aripiprazole | The metabolism of Aripiprazole can be decreased when combined with Idelalisib. |
| Aripiprazole | The metabolism of Aripiprazole lauroxil can be decreased when combined with Idelalisib. |
| Armodafinil | The metabolism of Idelalisib can be increased when combined with Armodafinil. |
| Arsenic trioxide | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Idelalisib. |
| Articaine | The risk or severity of methemoglobinemia can be increased when Idelalisib is combined with Articaine. |
| Asciminib | The serum concentration of Idelalisib can be increased when it is combined with Asciminib. |
| Asenapine | The metabolism of Asenapine can be decreased when combined with Idelalisib. |
| Astemizole | The metabolism of Idelalisib can be decreased when combined with Astemizole. |
| AstraZeneca | The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Idelalisib. |
| Asunaprevir | The metabolism of Idelalisib can be increased when combined with Asunaprevir. |
| Atazanavir | The metabolism of Idelalisib can be decreased when combined with Atazanavir. |
| Atogepant | The serum concentration of Atogepant can be increased when it is combined with Idelalisib. |
| Atorvastatin | The metabolism of Atorvastatin can be decreased when combined with Idelalisib. |
| Avacopan | The metabolism of Idelalisib can be decreased when combined with Avacopan. |
| Avanafil | The serum concentration of Avanafil can be increased when it is combined with Idelalisib. |
| Avatrombopag | Avatrombopag may decrease the excretion rate of Idelalisib which could result in a higher serum level. |
| Axitinib | The metabolism of Axitinib can be decreased when combined with Idelalisib. |
| Azacitidine | The risk or severity of adverse effects can be increased when Azacitidine is combined with Idelalisib. |
| Azathioprine | The risk or severity of adverse effects can be increased when Azathioprine is combined with Idelalisib. |
| Azithromycin | The metabolism of Idelalisib can be decreased when combined with Azithromycin. |
| Bacillus | The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Idelalisib. |
| Bacillus antigen | The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Idelalisib. |
| Bacillus calmette | The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Idelalisib. |
| Baricitinib | The risk or severity of adverse effects can be increased when Idelalisib is combined with Baricitinib. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Idelalisib. |
| Bazedoxifene | The metabolism of Bazedoxifene can be decreased when combined with Idelalisib. |
| BCG vaccine | The risk or severity of infection can be increased when BCG vaccine is combined with Idelalisib. |
| Beclomethasone | The metabolism of Idelalisib can be increased when combined with Beclomethasone dipropionate. |
| Belantamab | The serum concentration of Belantamab mafodotin can be increased when it is combined with Idelalisib. |
| Belatacept | The risk or severity of adverse effects can be increased when Belatacept is combined with Idelalisib. |
| Belimumab | The risk or severity of adverse effects can be increased when Belimumab is combined with Idelalisib. |
| Belinostat | The risk or severity of adverse effects can be increased when Belinostat is combined with Idelalisib. |
| Belumosudil | The risk or severity of adverse effects can be increased when Idelalisib is combined with Belumosudil. |
| Belzutifan | The serum concentration of Idelalisib can be decreased when it is combined with Belzutifan. |
| Bempedoic acid | The excretion of Bempedoic acid can be decreased when combined with Idelalisib. |
| Bendamustine | The risk or severity of adverse effects can be increased when Bendamustine is combined with Idelalisib. |
| Benzocaine | The risk or severity of methemoglobinemia can be increased when Idelalisib is combined with Benzocaine. |
| Benzyl alcohol | The risk or severity of methemoglobinemia can be increased when Idelalisib is combined with Benzyl alcohol. |
| Benzylpenicillin | The excretion of Benzylpenicillin can be decreased when combined with Idelalisib. |
| Berotralstat | The serum concentration of Idelalisib can be increased when it is combined with Berotralstat. |
| Betamethasone | The metabolism of Idelalisib can be increased when combined with Betamethasone. |
| Betamethasone | The metabolism of Idelalisib can be increased when combined with Betamethasone phosphate. |
| Betrixaban | The serum concentration of Betrixaban can be increased when it is combined with Idelalisib. |
| Bexarotene | The metabolism of Idelalisib can be increased when combined with Bexarotene. |
| Bicalutamide | The metabolism of Idelalisib can be decreased when combined with Bicalutamide. |
| Bifonazole | The metabolism of Idelalisib can be decreased when combined with Bifonazole. |
| Bimekizumab | The metabolism of Idelalisib can be increased when combined with Bimekizumab. |
| Binimetinib | The serum concentration of Binimetinib can be increased when it is combined with Idelalisib. |
| Bisoprolol | The serum concentration of Idelalisib can be increased when it is combined with Bisoprolol. |
| Bleomycin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Idelalisib. |
| Blinatumomab | The risk or severity of adverse effects can be increased when Blinatumomab is combined with Idelalisib. |
| Boceprevir | The metabolism of Idelalisib can be decreased when combined with Boceprevir. |
| Bordetella | The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Idelalisib. |
| Bortezomib | The risk or severity of adverse effects can be increased when Bortezomib is combined with Idelalisib. |
| Bosentan | The metabolism of Idelalisib can be increased when combined with Bosentan. |
| Bosutinib | The metabolism of Idelalisib can be decreased when combined with Bosutinib. |
| Brentuximab vedotin | The metabolism of Idelalisib can be decreased when combined with Brentuximab vedotin. |
| Brigatinib | The metabolism of Brigatinib can be decreased when combined with Idelalisib. |
| Brincidofovir | The serum concentration of Brincidofovir can be increased when it is combined with Idelalisib. |
| Brodalumab | The risk or severity of adverse effects can be increased when Idelalisib is combined with Brodalumab. |
| Budesonide | The metabolism of Idelalisib can be increased when combined with Budesonide. |
| Bupivacaine | The risk or severity of methemoglobinemia can be increased when Idelalisib is combined with Bupivacaine. |
| Buprenorphine | The metabolism of Idelalisib can be decreased when combined with Buprenorphine. |
| Busulfan | The risk or severity of adverse effects can be increased when Busulfan is combined with Idelalisib. |
| Butacaine | The risk or severity of methemoglobinemia can be increased when Idelalisib is combined with Butacaine. |
| Butalbital | The metabolism of Idelalisib can be increased when combined with Butalbital. |
| Butamben | The risk or severity of methemoglobinemia can be increased when Idelalisib is combined with Butamben. |
| Cabazitaxel | The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Idelalisib. |
| Cabergoline | The metabolism of Cabergoline can be decreased when combined with Idelalisib. |
| Caffeine | Caffeine may decrease the excretion rate of Idelalisib which could result in a higher serum level. |
| Calcitriol | The metabolism of Idelalisib can be increased when combined with Calcitriol. |
| Canagliflozin | The serum concentration of Idelalisib can be increased when it is combined with Canagliflozin. |
| Canakinumab | The metabolism of Idelalisib can be increased when combined with Canakinumab. |
| Candicidin | The metabolism of Idelalisib can be decreased when combined with Candicidin. |
| Cannabidiol | The metabolism of Idelalisib can be decreased when combined with Cannabidiol. |
| Capecitabine | The risk or severity of adverse effects can be increased when Capecitabine is combined with Idelalisib. |
| Capmatinib | The serum concentration of Capmatinib can be increased when it is combined with Idelalisib. |
| Capsaicin | The risk or severity of methemoglobinemia can be increased when Idelalisib is combined with Capsaicin. |
| Carbamazepine | The metabolism of Idelalisib can be increased when combined with Carbamazepine. |
| Carboplatin | The risk or severity of adverse effects can be increased when Carboplatin is combined with Idelalisib. |
| Carfilzomib | The risk or severity of adverse effects can be increased when Carfilzomib is combined with Idelalisib. |
| Carmustine | The risk or severity of adverse effects can be increased when Carmustine is combined with Idelalisib. |
| Carvedilol | The serum concentration of Idelalisib can be increased when it is combined with Carvedilol. |
| Caspofungin | The excretion of Caspofungin can be decreased when combined with Idelalisib. |
| Cefradine | The metabolism of Idelalisib can be increased when combined with Cefradine. |
| Cenobamate | The serum concentration of Idelalisib can be decreased when it is combined with Cenobamate. |
| Cephalexin | The metabolism of Idelalisib can be decreased when combined with Cephalexin. |
| Ceritinib | The metabolism of Idelalisib can be decreased when combined with Ceritinib. |
| Cerivastatin | The metabolism of Idelalisib can be increased when combined with Cerivastatin. |
| Certolizumab pegol | The metabolism of Idelalisib can be increased when combined with Certolizumab pegol. |
| Chlorambucil | The risk or severity of adverse effects can be increased when Chlorambucil is combined with Idelalisib. |
| Chloramphenicol | The metabolism of Idelalisib can be decreased when combined with Chloramphenicol. |
| Chloroprocaine | The risk or severity of methemoglobinemia can be increased when Idelalisib is combined with Chloroprocaine. |
| Chlorpromazine | The metabolism of Idelalisib can be increased when combined with Chlorpromazine. |
| Cholecystokinin | The excretion of Cholecystokinin can be decreased when combined with Idelalisib. |
| Cholesterol | Cholesterol may increase the excretion rate of Idelalisib which could result in a lower serum level and potentially a reduction in efficacy. |
| Cholic Acid | The excretion of Cholic Acid can be decreased when combined with Idelalisib. |
| Ciclesonide | The risk or severity of adverse effects can be increased when Ciclesonide is combined with Idelalisib. |
| Cilostazol | The metabolism of Cilostazol can be decreased when combined with Idelalisib. |
| Cimetidine | The metabolism of Idelalisib can be decreased when combined with Cimetidine. |
| Cinchocaine | The risk or severity of methemoglobinemia can be increased when Idelalisib is combined with Cinchocaine. |
| Ciprofloxacin | The metabolism of Idelalisib can be decreased when combined with Ciprofloxacin. |
| Cisapride | The metabolism of Idelalisib can be decreased when combined with Cisapride. |
| Cisplatin | The risk or severity of adverse effects can be increased when Cisplatin is combined with Idelalisib. |
| Citalopram | The metabolism of Idelalisib can be decreased when combined with Citalopram. |
| Cladribine | The risk or severity of adverse effects can be increased when Cladribine is combined with Idelalisib. |
| Clarithromycin | The metabolism of Idelalisib can be decreased when combined with Clarithromycin. |
| Clevidipine | The metabolism of Idelalisib can be increased when combined with Clevidipine. |
| Clindamycin | The metabolism of Clindamycin can be decreased when combined with Idelalisib. |
| Clobazam | The metabolism of Idelalisib can be increased when combined with Clobazam. |
| Clobetasol | The metabolism of Idelalisib can be increased when combined with Clobetasol propionate. |
| Clofarabine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Idelalisib. |
| Clofazimine | The metabolism of Idelalisib can be decreased when combined with Clofazimine. |
| Clofibrate | The metabolism of Idelalisib can be increased when combined with Clofibrate. |
| Clomifene | The serum concentration of Idelalisib can be increased when it is combined with Clomifene. |
| Clomipramine | The metabolism of Clomipramine can be decreased when combined with Idelalisib. |
| Clonidine | The metabolism of Clonidine can be decreased when combined with Idelalisib. |
| Clostridium | The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Idelalisib. |
| Clozapine | The metabolism of Idelalisib can be increased when combined with Clozapine. |
| Cobicistat | The metabolism of Idelalisib can be decreased when combined with Cobicistat. |
| Cobimetinib | The metabolism of Idelalisib can be decreased when combined with Cobimetinib. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Idelalisib is combined with Cocaine. |
| Colchicine | The metabolism of Colchicine can be decreased when combined with Idelalisib. |
| Conivaptan | The metabolism of Idelalisib can be decreased when combined with Conivaptan. |
| Cestrogens | The excretion of Conjugated estrogens can be decreased when combined with Idelalisib. |
| Copanlisib | The metabolism of Copanlisib can be decreased when combined with Idelalisib. |
| Corticotropin | The metabolism of Idelalisib can be increased when combined with Corticotropin. |
| Cortisone acetate | The metabolism of Idelalisib can be increased when combined with Cortisone acetate. |
| Corynebacterium | The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Idelalisib. |
| Crizotinib | The metabolism of Idelalisib can be decreased when combined with Crizotinib. |
| Curcumin | The metabolism of Idelalisib can be decreased when combined with Curcumin. |
| Cyclophosphamide | The metabolism of Idelalisib can be increased when combined with Cyclophosphamide. |
| Cyclosporine | Idelalisib may increase the immunosuppressive activities of Cyclosporine. |
| Cyproheptadine | The metabolism of Cyproheptadine can be decreased when combined with Idelalisib. |
| Cyproterone acetate | The metabolism of Idelalisib can be decreased when combined with Cyproterone acetate. |
| Cytarabine | The risk or severity of adverse effects can be increased when Cytarabine is combined with Idelalisib. |
| Dabigatran etexilate | The serum concentration of Idelalisib can be increased when it is combined with Dabigatran etexilate. |
| Dabrafenib | The serum concentration of Idelalisib can be decreased when it is combined with Dabrafenib. |
| Dacarbazine | The risk or severity of adverse effects can be increased when Dacarbazine is combined with Idelalisib. |
| Daclatasvir | Daclatasvir may decrease the excretion rate of Idelalisib which could result in a higher serum level. |
| Dacomitinib | The metabolism of Dacomitinib can be decreased when combined with Idelalisib. |
| Dactinomycin | The risk or severity of adverse effects can be increased when Dactinomycin is combined with Idelalisib. |
| Dalfopristin | The metabolism of Idelalisib can be decreased when combined with Dalfopristin. |
| Danazol | The metabolism of Idelalisib can be decreased when combined with Danazol. |
| Daptomycin | The serum concentration of Idelalisib can be increased when it is combined with Daptomycin. |
| Darbepoetin alfa | The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Idelalisib. |
| Darolutamide | The serum concentration of Idelalisib can be increased when it is combined with Darolutamide. |
| Darunavir | The serum concentration of Idelalisib can be increased when it is combined with Darunavir. |
| Dasabuvir | Dasabuvir may decrease the excretion rate of Idelalisib which could result in a higher serum level. |
| Dasatinib | The metabolism of Idelalisib can be decreased when combined with Dasatinib. |
| Daunorubicin | The metabolism of Idelalisib can be decreased when combined with Daunorubicin. |
| Decitabine | The risk or severity of adverse effects can be increased when Decitabine is combined with Idelalisib. |
| Deferasirox | The metabolism of Idelalisib can be increased when combined with Deferasirox. |
| Deflazacort | The metabolism of Idelalisib can be increased when combined with Deflazacort. |
| Delavirdine | The metabolism of Idelalisib can be decreased when combined with Delavirdine. |
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Idelalisib. |
| Desipramine | The metabolism of Idelalisib can be decreased when combined with Desipramine. |
| Desoximetasone | The risk or severity of adverse effects can be increased when Desoximetasone is combined with Idelalisib. |
| Desvenlafaxine | The metabolism of Idelalisib can be decreased when combined with Desvenlafaxine. |
| Deucravacitinib | The risk or severity of adverse effects can be increased when Idelalisib is combined with Deucravacitinib. |
| Dexamethasone | The metabolism of Idelalisib can be increased when combined with Dexamethasone. |
| Dexamethasone | The metabolism of Idelalisib can be increased when combined with Dexamethasone acetate. |
| Dexrazoxane | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Idelalisib. |
| Dextropropoxyph | The metabolism of Idelalisib can be decreased when combined with Dextropropoxyphene. |
| Dicloxacillin | The metabolism of Idelalisib can be increased when combined with Dicloxacillin. |
| Diethylstilbestrol | The metabolism of Idelalisib can be decreased when combined with Diethylstilbestrol. |
| Difluocortolone | The metabolism of Idelalisib can be increased when combined with Difluocortolone. |
| Digitoxin | The metabolism of Digitoxin can be decreased when combined with Idelalisib. |
| Digoxin | The serum concentration of Digoxin can be increased when it is combined with Idelalisib. |
| Dihydroergocornine | The metabolism of Idelalisib can be decreased when combined with Dihydroergocornine. |
| Dihydroergocristine | The metabolism of Idelalisib can be decreased when combined with Dihydroergocristine. |
| Dihydroergotamine | The metabolism of Idelalisib can be decreased when combined with Dihydroergotamine. |
| Diltiazem | The metabolism of Idelalisib can be decreased when combined with Diltiazem. |
| Dimethyl fumarate | The risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Idelalisib. |
| Dimethyl sulfoxide | The metabolism of Idelalisib can be decreased when combined with Dimethyl sulfoxide. |
| Dinoprostone | The excretion of Dinoprostone can be decreased when combined with Idelalisib. |
| Dinutuximab | The risk or severity of adverse effects can be increased when Idelalisib is combined with Dinutuximab. |
| Diosmin | The metabolism of Idelalisib can be decreased when combined with Diosmin. |
| Diphenhydramine | The risk or severity of methemoglobinemia can be increased when Idelalisib is combined with Diphenhydramine. |
| Diroximel fumarate | The risk or severity of adverse effects can be increased when Idelalisib is combined with Diroximel fumarate. |
| Docetaxel | The metabolism of Idelalisib can be decreased when combined with Docetaxel. |
| Dofetilide | The metabolism of Dofetilide can be decreased when combined with Idelalisib. |
| Dolutegravir | The serum concentration of Idelalisib can be increased when it is combined with Dolutegravir. |
| Doxazosin | The metabolism of Idelalisib can be decreased when combined with Doxazosin. |
| Doxorubicin | The metabolism of Idelalisib can be decreased when combined with Doxorubicin. |
| Dronabinol | The serum concentration of Dronabinol can be increased when it is combined with Idelalisib. |
| Dronedarone | The serum concentration of Idelalisib can be increased when it is combined with Dronedarone. |
| Drospirenone | The metabolism of Idelalisib can be decreased when combined with Drospirenone. |
| Duvelisib | The metabolism of Idelalisib can be decreased when combined with Duvelisib. |
| Dyclonine | The risk or severity of methemoglobinemia can be increased when Idelalisib is combined with Dyclonine. |
| Ebastine | The metabolism of Idelalisib can be decreased when combined with Ebastine. |
| Ebola vaccine | The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Idelalisib. |
| Echinacea | The metabolism of Idelalisib can be increased when combined with Echinacea. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Idelalisib. |
| Edoxaban | The serum concentration of Edoxaban can be increased when it is combined with Idelalisib. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Idelalisib. |
| Efavirenz | The metabolism of Idelalisib can be decreased when combined with Efavirenz. |
| Elagolix | The serum concentration of Idelalisib can be increased when it is combined with Elagolix. |
| Elbasvir | Elbasvir may decrease the excretion rate of Idelalisib which could result in a higher serum level. |
| Elexacaftor | The metabolism of Idelalisib can be decreased when combined with Elexacaftor. |
| Eliglustat | The metabolism of Eliglustat can be decreased when combined with Idelalisib. |
| Eltrombopag | Eltrombopag may decrease the excretion rate of Idelalisib which could result in a higher serum level. |
| Eluxadoline | The serum concentration of Eluxadoline can be increased when it is combined with Idelalisib. |
| Elvitegravir | The metabolism of Idelalisib can be decreased when combined with Elvitegravir. |
| Emapalumab | The metabolism of Idelalisib can be increased when combined with Emapalumab. |
| Enalapril | The excretion of Enalapril can be decreased when combined with Idelalisib. |
| Enasidenib | The metabolism of Idelalisib can be increased when combined with Enasidenib. |
| Enfortumab | The serum concentration of Enfortumab vedotin can be increased when it is combined with Idelalisib. |
| Entrectinib | The metabolism of Entrectinib can be decreased when combined with Idelalisib. |
| Enzalutamide | The serum concentration of Idelalisib can be decreased when it is combined with Enzalutamide. |
| Epinephrine | The metabolism of Idelalisib can be decreased when combined with Epinephrine. |
| Epirubicin | The risk or severity of adverse effects can be increased when Epirubicin is combined with Idelalisib. |
| Erdafitinib | The serum concentration of Idelalisib can be increased when it is combined with Erdafitinib. |
| Ergotamine | The metabolism of Idelalisib can be decreased when combined with Ergotamine. |
| Eribulin | The risk or severity of adverse effects can be increased when Eribulin is combined with Idelalisib. |
| Erlotinib | The metabolism of Idelalisib can be decreased when combined with Erlotinib. |
| Ertugliflozin | The serum concentration of Ertugliflozin can be increased when it is combined with Idelalisib. |
| Erythromycin | The metabolism of Idelalisib can be decreased when combined with Erythromycin. |
| Erythropoietin | The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Idelalisib. |
| Esketamine | The metabolism of Idelalisib can be increased when combined with Esketamine. |
| Eslicarbazepine | The metabolism of Idelalisib can be increased when combined with Eslicarbazepine. |
| Eslicarbazepine | The metabolism of Idelalisib can be increased when combined with Eslicarbazepine acetate. |
| Estetrol | The metabolism of Idelalisib can be decreased when combined with Estetrol. |
| Estradiol | Estradiol may decrease the excretion rate of Idelalisib which could result in a higher serum level. |
| Estradiol acetate | The metabolism of Idelalisib can be increased when combined with Estradiol acetate. |
| Estradiol benzoate | The metabolism of Idelalisib can be increased when combined with Estradiol benzoate. |
| Estradiol cypionate | The metabolism of Idelalisib can be increased when combined with Estradiol cypionate. |
| Estradiol dienanthate | The metabolism of Idelalisib can be increased when combined with Estradiol dienanthate. |
| Estradiol valerate | The metabolism of Idelalisib can be increased when combined with Estradiol valerate. |
| Estramustine | The risk or severity of adverse effects can be increased when Estramustine is combined with Idelalisib. |
| Eszopiclone | The metabolism of Eszopiclone can be decreased when combined with Idelalisib. |
| Etanercept | The metabolism of Idelalisib can be increased when combined with Etanercept. |
| Ethambutol | The metabolism of Idelalisib can be decreased when combined with Ethambutol. |
| Ethanol | The metabolism of Idelalisib can be increased when combined with Ethanol. |
| Ethinylestradiol | The metabolism of Ethinylestradiol can be decreased when combined with Idelalisib. |
| Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Idelalisib is combined with Ethyl chloride. |
| Etidocaine | The risk or severity of methemoglobinemia can be increased when Idelalisib is combined with Etidocaine. |
| Etoposide | The risk or severity of adverse effects can be increased when Etoposide is combined with Idelalisib. |
| Etoricoxib | The metabolism of Idelalisib can be decreased when combined with Etoricoxib. |
| Etravirine | The metabolism of Idelalisib can be increased when combined with Etravirine. |
| Everolimus | The risk or severity of adverse effects can be increased when Everolimus is combined with Idelalisib. |
| Ezetimibe | The excretion of Ezetimibe can be decreased when combined with Idelalisib. |
| Ezogabine | The metabolism of Ezogabine can be decreased when combined with Idelalisib. |
| Famtozinameran | The therapeutic efficacy of Famtozinameran can be decreased when used in combination with Idelalisib. |
| Favipiravir | The serum concentration of Idelalisib can be increased when it is combined with Favipiravir. |
| Febuxostat | The excretion of Idelalisib can be decreased when combined with Febuxostat. |
| Fedratinib | Fedratinib may decrease the excretion rate of Idelalisib which could result in a higher serum level. |
| Felbamate | The metabolism of Idelalisib can be increased when combined with Felbamate. |
| Fenofibrate | The metabolism of Idelalisib can be decreased when combined with Fenofibrate. |
| Fentanyl | The metabolism of Fentanyl can be decreased when combined with Idelalisib. |
| Fexinidazole | The metabolism of Idelalisib can be decreased when combined with Fexinidazole. |
| Fexofenadine | The serum concentration of Idelalisib can be increased when it is combined with Fexofenadine. |
| Filgotinib | The risk or severity of adverse effects can be increased when Idelalisib is combined with Filgotinib. |
| Finerenone | The serum concentration of Finerenone can be increased when it is combined with Idelalisib. |
| Fingolimod | Idelalisib may increase the immunosuppressive activities of Fingolimod. |
| Flibanserin | The serum concentration of Idelalisib can be increased when it is combined with Flibanserin. |
| Floxuridine | The risk or severity of adverse effects can be increased when Floxuridine is combined with Idelalisib. |
| Flucloxacillin | The metabolism of Idelalisib can be increased when combined with Flucloxacillin. |
| Fluconazole | The metabolism of Idelalisib can be decreased when combined with Fluconazole. |
| Flucytosine | The risk or severity of adverse effects can be increased when Flucytosine is combined with Idelalisib. |
| Fludarabine | The risk or severity of adverse effects can be increased when Fludarabine is combined with Idelalisib. |
| Fludrocortisone | The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Idelalisib. |
| Flunisolide | The metabolism of Idelalisib can be increased when combined with Flunisolide. |
| Fluocinolone | The metabolism of Idelalisib can be increased when combined with Fluocinolone acetonide. |
| Fluocinonide | The metabolism of Idelalisib can be increased when combined with Fluocinonide. |
| Fluocortolone | The metabolism of Idelalisib can be increased when combined with Fluocortolone. |
| Fluorometholone | The risk or severity of adverse effects can be increased when Fluorometholone is combined with Idelalisib. |
| Fluorouracil | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Idelalisib. |
| Fluoxetine | The metabolism of Idelalisib can be decreased when combined with Fluoxetine. |
| Fluprednisolone | The risk or severity of adverse effects can be increased when Idelalisib is combined with Fluprednisolone. |
| Fluticasone | The metabolism of Idelalisib can be increased when combined with Fluticasone. |
| Fluticasone furoate | The metabolism of Idelalisib can be increased when combined with Fluticasone furoate. |
| Fluticasone | The metabolism of Idelalisib can be decreased when combined with Fluticasone propionate. |
| Fluvastatin | The excretion of Fluvastatin can be decreased when combined with Idelalisib. |
| Fluvoxamine | The metabolism of Idelalisib can be decreased when combined with Fluvoxamine. |
| Formestane | The metabolism of Idelalisib can be increased when combined with Formestane. |
| Fosamprenavir | The metabolism of Idelalisib can be decreased when combined with Fosamprenavir. |
| Fosaprepitant | The metabolism of Idelalisib can be increased when combined with Fosaprepitant. |
| Fosnetupitant | The metabolism of Idelalisib can be decreased when combined with Fosnetupitant. |
| Fosphenytoin | The metabolism of Idelalisib can be increased when combined with Fosphenytoin. |
| Fostamatinib | The metabolism of Idelalisib can be decreased when combined with Fostamatinib. |
| Fostemsavir | Fostemsavir may decrease the excretion rate of Idelalisib which could result in a higher serum level. |
| Fusidic acid | The metabolism of Idelalisib can be decreased when combined with Fusidic acid. |
| Futibatinib | The serum concentration of Futibatinib can be increased when it is combined with Idelalisib. |
| Gadoxetic acid | The excretion of Gadoxetic acid can be decreased when combined with Idelalisib. |
| Gallium nitrate | The risk or severity of adverse effects can be increased when Gallium nitrate is combined with Idelalisib. |
| Gefitinib | Gefitinib may decrease the excretion rate of Idelalisib which could result in a higher serum level. |
| Gemcitabine | The risk or severity of adverse effects can be increased when Gemcitabine is combined with Idelalisib. |
| Gemtuzumab | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Idelalisib. |
| Gilteritinib | The metabolism of Idelalisib can be decreased when combined with Gilteritinib. |
| Ginkgo biloba | The metabolism of Idelalisib can be decreased when combined with Ginkgo biloba. |
| Glasdegib | Glasdegib may decrease the excretion rate of Idelalisib which could result in a higher serum level. |
| Glatiramer | The risk or severity of adverse effects can be increased when Glatiramer is combined with Idelalisib. |
| Glecaprevir | The metabolism of Idelalisib can be decreased when combined with Glecaprevir. |
| Glyburide | The metabolism of Idelalisib can be decreased when combined with Glyburide. |
| Glycerol | The metabolism of Idelalisib can be increased when combined with Glycerol phenylbutyrate. |
| Golimumab | The metabolism of Idelalisib can be increased when combined with Golimumab. |
| Grazoprevir | Grazoprevir may decrease the excretion rate of Idelalisib which could result in a higher serum level. |
| Griseofulvin | The metabolism of Idelalisib can be increased when combined with Griseofulvin. |
| Guselkumab | The risk or severity of adverse effects can be increased when Idelalisib is combined with Guselkumab. |
| Haemophilus | The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Idelalisib. |
| Haloperidol | The serum concentration of Haloperidol can be increased when it is combined with Idelalisib. |
| Hepatitis A Vaccine | The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Idelalisib. |
| Hepatitis B Vaccine | The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Idelalisib. |
| Human adenovirus | The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Idelalisib. |
| Hydralazine | The metabolism of Idelalisib can be decreased when combined with Hydralazine. |
| Hydrocortamate | The metabolism of Idelalisib can be increased when combined with Hydrocortamate. |
| Hydrocortisone | The metabolism of Idelalisib can be increased when combined with Hydrocortisone. |
| Hydrocortisone | The metabolism of Idelalisib can be increased when combined with Hydrocortisone acetate. |
| Hydrocortisone | The metabolism of Idelalisib can be increased when combined with Hydrocortisone butyrate. |
| Hydrocortisone | The metabolism of Idelalisib can be increased when combined with Hydrocortisone succinate. |
| Hydroxychloroquine | The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Idelalisib. |
| Hydroxyurea | The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Idelalisib. |
| Hydroxyzine | The metabolism of Hydroxyzine can be decreased when combined with Idelalisib. |
| Ibritumomab | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Idelalisib. |
| Ibrutinib | The metabolism of Ibrutinib can be decreased when combined with Idelalisib. |
| Idarubicin | The risk or severity of adverse effects can be increased when Idarubicin is combined with Idelalisib. |
| Ifosfamide | The metabolism of Idelalisib can be increased when combined with Ifosfamide. |
| Iloperidone | The metabolism of Iloperidone can be decreased when combined with Idelalisib. |
| Imatinib | The serum concentration of Idelalisib can be increased when it is combined with Imatinib. |
| Imipramine | The serum concentration of Imipramine can be increased when it is combined with Idelalisib. |
| Indacaterol | The serum concentration of Idelalisib can be increased when it is combined with Indacaterol. |
| Indinavir | The metabolism of Idelalisib can be decreased when combined with Indinavir. |
| Indomethacin | The risk or severity of adverse effects can be increased when Indomethacin is combined with Idelalisib. |
| Inebilizumab | The risk or severity of infection can be increased when Idelalisib is combined with Inebilizumab. |
| Infigratinib | The metabolism of Idelalisib can be decreased when combined with Infigratinib. |
| Infliximab | The metabolism of Idelalisib can be increased when combined with Infliximab. |
| Ketazolam | The metabolism of Idelalisib can be decreased when combined with Ketazolam. |
| Ketoconazole | The metabolism of Idelalisib can be decreased when combined with Ketoconazole. |
| Lacosamide | The metabolism of Idelalisib can be decreased when combined with Lacosamide. |
| Lamotrigine | The metabolism of Lamotrigine can be decreased when combined with Idelalisib. |
| Lanreotide | The metabolism of Idelalisib can be decreased when combined with Lanreotide. |
| Lansoprazole | Lansoprazole may decrease the excretion rate of Idelalisib which could result in a higher serum level. |
| Lapatinib | The metabolism of Idelalisib can be decreased when combined with Lapatinib. |
| Larotrectinib | The serum concentration of Larotrectinib can be increased when it is combined with Idelalisib. |
| Lasmiditan | The serum concentration of Idelalisib can be increased when it is combined with Lasmiditan. |
| Ledipasvir | Ledipasvir may decrease the excretion rate of Idelalisib which could result in a higher serum level. |
| Lefamulin | The serum concentration of Idelalisib can be increased when it is combined with Lefamulin. |
| Leflunomide | The risk or severity of adverse effects can be increased when Idelalisib is combined with Leflunomide. |
| Lemborexant | The serum concentration of Lemborexant can be increased when it is combined with Idelalisib. |
| Lenalidomide | The risk or severity of adverse effects can be increased when Lenalidomide is combined with Idelalisib. |
| Lenvatinib | The serum concentration of Lenvatinib can be increased when it is combined with Idelalisib. |
| Lesinurad | The metabolism of Idelalisib can be increased when combined with Lesinurad. |
| Letermovir | The metabolism of Idelalisib can be decreased when combined with Letermovir. |
| Levacetylmet | The metabolism of Levacetylmethadol can be decreased when combined with Idelalisib. |
| Levamlodipine | The serum concentration of Levamlodipine can be increased when it is combined with Idelalisib. |
| Levobupivacaine | The risk or severity of methemoglobinemia can be increased when Idelalisib is combined with Levobupivacaine. |
| Levoketoconazole | The metabolism of Idelalisib can be decreased when combined with Levoketoconazole. |
| Levosalbutamol | The excretion of Levosalbutamol can be decreased when combined with Idelalisib. |
| Lidocaine | The risk or severity of methemoglobinemia can be increased when Idelalisib is combined with Lidocaine. |
| Linagliptin | The metabolism of Idelalisib can be decreased when combined with Linagliptin. |
| Linezolid | The risk or severity of adverse effects can be increased when Linezolid is combined with Idelalisib. |
| Liothyronine | The excretion of Liothyronine can be decreased when combined with Idelalisib. |
| Liotrix | The excretion of Liotrix can be decreased when combined with Idelalisib. |
| Lomitapide | The metabolism of Idelalisib can be decreased when combined with Lomitapide. |
| Lomustine | The risk or severity of adverse effects can be increased when Lomustine is combined with Idelalisib. |
| Lonafarnib | The metabolism of Idelalisib can be decreased when combined with Lonafarnib. |
| Loncastuximab | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Idelalisib. |
| Loperamide | The serum concentration of Idelalisib can be increased when it is combined with Loperamide. |
| Lopinavir | The serum concentration of Idelalisib can be increased when it is combined with Lopinavir. |
| Lorlatinib | The metabolism of Idelalisib can be increased when combined with Lorlatinib. |
| Losartan | The metabolism of Idelalisib can be decreased when combined with Losartan. |
| Lovastatin | The metabolism of Lovastatin can be decreased when combined with Idelalisib. |
| Loxapine | The serum concentration of Idelalisib can be increased when it is combined with Loxapine. |
| Lumacaftor | The serum concentration of Idelalisib can be decreased when it is combined with Lumacaftor. |
| Lumateperone | The serum concentration of Lumateperone can be increased when it is combined with Idelalisib. |
| Lusutrombopag | The serum concentration of Lusutrombopag can be increased when it is combined with Idelalisib. |
| Magnesium | The serum concentration of Magnesium can be decreased when it is combined with Idelalisib. |
| Manidipine | The metabolism of Idelalisib can be decreased when combined with Manidipine. |
| Mannitol | The serum concentration of Idelalisib can be increased when it is combined with Mannitol. |
| Maribavir | Maribavir may decrease the excretion rate of Idelalisib which could result in a higher serum level. |
| Mavacamten | The serum concentration of Idelalisib can be decreased when it is combined with Mavacamten. |
| Measles virus | The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Idelalisib. |
| Mechlorethamine | The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Idelalisib. |
| Medroxyprogeste | The metabolism of Idelalisib can be increased when combined with Medroxyprogesterone acetate. |
| Mefloquine | The serum concentration of Idelalisib can be increased when it is combined with Mefloquine. |
| Meloxicam | The risk or severity of methemoglobinemia can be increased when Idelalisib is combined with Meloxicam. |
| Melphalan | The risk or severity of adverse effects can be increased when Melphalan is combined with Idelalisib. |
| Meningococcal | The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Idelalisib. |
| Meperidine | The metabolism of Idelalisib can be decreased when combined with Meperidine. |
| Mepivacaine | The risk or severity of methemoglobinemia can be increased when Idelalisib is combined with Mepivacaine. |
| Mepolizumab | The risk or severity of adverse effects can be increased when Mepolizumab is combined with Idelalisib. |
| Meprednisone | The metabolism of Idelalisib can be increased when combined with Meprednisone. |
| Mercaptopurine | The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Idelalisib. |
| Methadone | The metabolism of Idelalisib can be decreased when combined with Methadone. |
| Methimazole | The metabolism of Idelalisib can be decreased when combined with Methimazole. |
| Methotrexate | The risk or severity of adverse effects can be increased when Methotrexate is combined with Idelalisib. |
| Methoxy | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Idelalisib. |
| Methylene blue | The metabolism of Idelalisib can be decreased when combined with Methylene blue. |
| Methylergometrine | The metabolism of Idelalisib can be decreased when combined with Methylergometrine. |
| Methylphenobarbital | The metabolism of Idelalisib can be increased when combined with Methylphenobarbital. |
| Methylprednisolone | The metabolism of Idelalisib can be increased when combined with Methylprednisolone. |
| Methylprednisone | The metabolism of Idelalisib can be decreased when combined with Methylprednisone. |
| Methysergide | The metabolism of Idelalisib can be decreased when combined with Methysergide. |
| Metreleptin | The metabolism of Idelalisib can be increased when combined with Metreleptin. |
| Metronidazole | The metabolism of Idelalisib can be decreased when combined with Metronidazole. |
| Metyrapone | The metabolism of Idelalisib can be increased when combined with Metyrapone. |
| Miconazole | The metabolism of Idelalisib can be decreased when combined with Miconazole. |
| Midazolam | The serum concentration of Midazolam can be increased when it is combined with Idelalisib. |
| Midostaurin | The metabolism of Idelalisib can be decreased when combined with Midostaurin. |
| Mifepristone | The metabolism of Idelalisib can be increased when combined with Mifepristone. |
| Milnacipran | The metabolism of Idelalisib can be decreased when combined with Milnacipran. |
| Miocamycin | The metabolism of Idelalisib can be decreased when combined with Miocamycin. |
| Mirabegron | The serum concentration of Idelalisib can be increased when it is combined with Mirabegron. |
| Mirtazapine | The metabolism of Idelalisib can be decreased when combined with Mirtazapine. |
| Mitapivat | The metabolism of Idelalisib can be increased when combined with Mitapivat. |
| Mitomycin | The risk or severity of adverse effects can be increased when Mitomycin is combined with Idelalisib. |
| Mitotane | The metabolism of Idelalisib can be increased when combined with Mitotane. |
| Mitoxantrone | The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Idelalisib. |
| Mobocertinib | The serum concentration of Idelalisib can be decreased when it is combined with Mobocertinib. |
| Modafinil | The metabolism of Idelalisib can be increased when combined with Modafinil. |
| COVID-19 Vaccine | The therapeutic efficacy of Moderna COVID-19 Vaccine can be decreased when used in combination with Idelalisib. |
| Modified vaccinia | The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Idelalisib. |
| Mometasone fur | The metabolism of Idelalisib can be increased when combined with Mometasone furoate. |
| Monomethyl fum | The risk or severity of adverse effects can be increased when Idelalisib is combined with Monomethyl fumarate. |
| Morphine | The serum concentration of Idelalisib can be increased when it is combined with Morphine. |
| Mosunetuzumab | The metabolism of Idelalisib can be decreased when combined with Mosunetuzumab. |
| Mumps virus | The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Idelalisib. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Idelalisib. |
| Mycophenolate | The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Idelalisib. |
| Mycophenolic acid | The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Idelalisib. |
| Nafcillin | The metabolism of Idelalisib can be increased when combined with Nafcillin. |
| Naloxone | The metabolism of Idelalisib can be decreased when combined with Naloxone. |
| Natalizumab | The risk or severity of adverse effects can be increased when Idelalisib is combined with Natalizumab. |
| Nefazodone | The metabolism of Idelalisib can be decreased when combined with Nefazodone. |
| Nelarabine | The risk or severity of adverse effects can be increased when Nelarabine is combined with Idelalisib. |
| Nelfinavir | The metabolism of Idelalisib can be decreased when combined with Nelfinavir. |
| Neratinib | The metabolism of Neratinib can be decreased when combined with Idelalisib. |
| Netupitant | The metabolism of Idelalisib can be decreased when combined with Netupitant. |
| Niacin | The metabolism of Idelalisib can be decreased when combined with Niacin. |
| Nicardipine | The metabolism of Idelalisib can be decreased when combined with Nicardipine. |
| Nilotinib | The metabolism of Idelalisib can be decreased when combined with Nilotinib. |
| Nilvadipine | The metabolism of Idelalisib can be decreased when combined with Nilvadipine. |
| Nintedanib | The metabolism of Idelalisib can be decreased when combined with Nintedanib. |
| Norethisterone | The metabolism of Idelalisib can be decreased when combined with Norethisterone. |
| Norgestimate | The metabolism of Idelalisib can be increased when combined with Norgestimate. |
| Nortriptyline | The metabolism of Nortriptyline can be decreased when combined with Idelalisib. |
| Noscapine | The metabolism of Idelalisib can be decreased when combined with Noscapine. |
| Novobiocin | Novobiocin may decrease the excretion rate of Idelalisib which could result in a higher serum level. |
| Nuvaxovid | The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Idelalisib. |
| Obinutuzumab | The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Idelalisib. |
| Ocrelizumab | The risk or severity of adverse effects can be increased when Idelalisib is combined with Ocrelizumab. |
| Octreotide | The serum concentration of Idelalisib can be increased when it is combined with Octreotide. |
| Ofatumumab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Idelalisib. |
| Olanzapine | The metabolism of Olanzapine can be decreased when combined with Idelalisib. |
| Olaparib | The metabolism of Idelalisib can be decreased when combined with Olaparib. |
| Omadacycline | The serum concentration of Omadacycline can be increased when it is combined with Idelalisib. |
| Ombitasvir | The serum concentration of Ombitasvir can be increased when it is combined with Idelalisib. |
| Omeprazole | The metabolism of Idelalisib can be increased when combined with Omeprazole. |
| Oritavancin | The metabolism of Idelalisib can be increased when combined with Oritavancin. |
| Orphenadrine | The metabolism of Idelalisib can be decreased when combined with Orphenadrine. |
| Osilodrostat | The metabolism of Idelalisib can be decreased when combined with Osilodrostat. |
| Osimertinib | The metabolism of Osimertinib can be decreased when combined with Idelalisib. |
| Oteseconazole | The serum concentration of Idelalisib can be increased when it is combined with Oteseconazole. |
| Ouabain | The excretion of Ouabain can be decreased when combined with Idelalisib. |
| Oxaliplatin | The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Idelalisib. |
| Oxcarbazepine | The metabolism of Idelalisib can be increased when combined with Oxcarbazepine. |
| Oxetacaine | The risk or severity of methemoglobinemia can be increased when Idelalisib is combined with Oxetacaine. |
| Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Idelalisib is combined with Oxybuprocaine. |
| Oxybutynin | The metabolism of Idelalisib can be decreased when combined with Oxybutynin. |
| Ozanimod | The risk or severity of adverse effects can be increased when Idelalisib is combined with Ozanimod. |
| Paclitaxel | The metabolism of Idelalisib can be increased when combined with Paclitaxel. |
| Pacritinib | The serum concentration of Idelalisib can be increased when it is combined with Pacritinib. |
| Palbociclib | The metabolism of Idelalisib can be decreased when combined with Palbociclib. |
| Paliperidone | The serum concentration of Idelalisib can be increased when it is combined with Paliperidone. |
| Panobinostat | The risk or severity of adverse effects can be increased when Panobinostat is combined with Idelalisib. |
| Pantoprazole | Pantoprazole may decrease the excretion rate of Idelalisib which could result in a higher serum level. |
| Paricalcitol | The metabolism of Paricalcitol can be decreased when combined with Idelalisib. |
| Paritaprevir | Paritaprevir may decrease the excretion rate of Idelalisib which could result in a higher serum level. |
| Pasireotide | The metabolism of Idelalisib can be decreased when combined with Pasireotide. |
| Pazopanib | The metabolism of Idelalisib can be decreased when combined with Pazopanib. |
| Pegaspargase | The risk or severity of adverse effects can be increased when Pegaspargase is combined with Idelalisib. |
| Pegcetacoplan | The risk or severity of adverse effects can be increased when Idelalisib is combined with Pegcetacoplan. |
| Peginesatide | The risk or severity of Thrombosis can be increased when Peginesatide is combined with Idelalisib. |
| Peginterferon alfa-2a | The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Idelalisib. |
| Peginterferon alfa-2b | The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Idelalisib. |
| Peginterferon beta-1a | The risk or severity of adverse effects can be increased when Idelalisib is combined with Peginterferon beta-1a. |
| Pemetrexed | The risk or severity of adverse effects can be increased when Pemetrexed is combined with Idelalisib. |
| Penicillamine | The risk or severity of adverse effects can be increased when Penicillamine is combined with Idelalisib. |
| Pentobarbital | The metabolism of Idelalisib can be increased when combined with Pentobarbital. |
| Pentostatin | The risk or severity of adverse effects can be increased when Pentostatin is combined with Idelalisib. |
| Perampanel | The metabolism of Idelalisib can be increased when combined with Perampanel. |
| Pertussis vaccine | The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Idelalisib. |
| Pexidartinib | Idelalisib may increase the hepatotoxic activities of Pexidartinib. |
| Phenobarbital | The metabolism of Idelalisib can be increased when combined with Phenobarbital. |
| Phenol | The risk or severity of methemoglobinemia can be increased when Idelalisib is combined with Phenol. |
| Phenprocoumon | The metabolism of Phenprocoumon can be decreased when combined with Idelalisib. |
| Phenylalanine | The risk or severity of adverse effects can be increased when Phenylalanine is combined with Idelalisib. |
| Phenylbutazone | The metabolism of Idelalisib can be increased when combined with Phenylbutazone. |
| Phenytoin | The metabolism of Idelalisib can be increased when combined with Phenytoin. |
| Pibrentasvir | Pibrentasvir may decrease the excretion rate of Idelalisib which could result in a higher serum level. |
| Pimavanserin | The metabolism of Idelalisib can be decreased when combined with Pimavanserin. |
| Pimecrolimus | The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Idelalisib. |
| Pimozide | The metabolism of Idelalisib can be decreased when combined with Pimozide. |
| Piperaquine | The metabolism of Idelalisib can be decreased when combined with Piperaquine. |
| Pirfenidone | The risk or severity of adverse effects can be increased when Pirfenidone is combined with Idelalisib. |
| Pitavastatin | The excretion of Pitavastatin can be decreased when combined with Idelalisib. |
| Pitolisant | The serum concentration of Idelalisib can be decreased when it is combined with Pitolisant. |
| Pomalidomide | The risk or severity of adverse effects can be increased when Pomalidomide is combined with Idelalisib. |
| Ponatinib | The risk or severity of adverse effects can be increased when Ponatinib is combined with Idelalisib. |
| Ponesimod | The risk or severity of adverse effects can be increased when Idelalisib is combined with Ponesimod. |
| Posaconazole | The metabolism of Idelalisib can be decreased when combined with Posaconazole. |
| Pralatrexate | The risk or severity of adverse effects can be increased when Pralatrexate is combined with Idelalisib. |
| Pralsetinib | The metabolism of Idelalisib can be increased when combined with Pralsetinib. |
| Pramocaine | The risk or severity of methemoglobinemia can be increased when Idelalisib is combined with Pramocaine. |
| Pravastatin | Pravastatin may decrease the excretion rate of Idelalisib which could result in a higher serum level. |
| Prednisolone | The metabolism of Idelalisib can be increased when combined with Prednisolone. |
| Prednisolone | The metabolism of Idelalisib can be increased when combined with Prednisolone acetate. |
| Prednisolone | The metabolism of Idelalisib can be increased when combined with Prednisolone phosphate. |
| Prednisone | The risk or severity of adverse effects can be increased when Prednisone is combined with Idelalisib. |
| Prednisone ace | The metabolism of Idelalisib can be increased when combined with Prednisone acetate. |
| Pretomanid | The metabolism of Idelalisib can be decreased when combined with Pretomanid. |
| Prilocaine | The risk or severity of methemoglobinemia can be increased when Idelalisib is combined with Prilocaine. |
| Primaquine | The metabolism of Idelalisib can be decreased when combined with Primaquine. |
| Primidone | The metabolism of Idelalisib can be increased when combined with Primidone. |
| Probenecid | The metabolism of Idelalisib can be increased when combined with Probenecid. |
| Procaine | The risk or severity of methemoglobinemia can be increased when Idelalisib is combined with Procaine. |
| Procarbazine | The risk or severity of adverse effects can be increased when Procarbazine is combined with Idelalisib. |
| Progesterone | Progesterone may decrease the excretion rate of Idelalisib which could result in a higher serum level. |
| Propafenone | The serum concentration of Idelalisib can be increased when it is combined with Propafenone. |
| Proparacaine | The risk or severity of methemoglobinemia can be increased when Idelalisib is combined with Proparacaine. |
| Propofol | The metabolism of Idelalisib can be decreased when combined with Propofol. |
| Propoxycaine | The risk or severity of methemoglobinemia can be increased when Idelalisib is combined with Propoxycaine. |
| Propylthiouracil | The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Idelalisib. |
| Prucalopride | The metabolism of Prucalopride can be decreased when combined with Idelalisib. |
| Quinidine | The metabolism of Idelalisib can be decreased when combined with Quinidine |
| Quinine | The metabolism of Idelalisib can be increased when combined with Quinine. |
| Quinupristin | The metabolism of Idelalisib can be decreased when combined with Quinupristin. |
| Rabeprazole | Rabeprazole may decrease the excretion rate of Idelalisib which could result in a higher serum level. |
| Rabies globulin | The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Idelalisib. |
| Rabies virus | The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Idelalisib. |
| Rabies antigen, B | The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Idelalisib. |
| Raloxifene | The metabolism of Idelalisib can be decreased when combined with Raloxifene. |
| Raltitrexed | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Idelalisib. |
| Ranolazine | The serum concentration of Idelalisib can be increased when it is combined with Ranolazine. |
| Ravulizumab | The risk or severity of adverse effects can be increased when Idelalisib is combined with Ravulizumab. |
| Regorafenib | The metabolism of Regorafenib can be decreased when combined with Idelalisib. |
| Relugolix | The serum concentration of Relugolix can be increased when it is combined with Idelalisib. |
| Remdesivir | The metabolism of Idelalisib can be decreased when combined with Remdesivir. |
| Repaglinide | The excretion of Repaglinide can be decreased when combined with Idelalisib. |
| Reserpine | The serum concentration of Idelalisib can be increased when it is combined with Reserpine. |
| Retapamulin | The metabolism of Retapamulin can be decreased when combined with Idelalisib. |
| Revefenacin | Idelalisib may decrease the excretion rate of Revefenacin which could result in a higher serum level. |
| Ribociclib | The metabolism of Idelalisib can be decreased when combined with Ribociclib. |
| Rifabutin | The metabolism of Idelalisib can be increased when combined with Rifabutin. |
| Rifampicin | The metabolism of Idelalisib can be increased when combined with Rifampicin. |
| Rifamycin | The metabolism of Idelalisib can be increased when combined with Rifamycin. |
| Rifapentine | The metabolism of Idelalisib can be increased when combined with Rifapentine. |
| Rilonacept | The metabolism of Idelalisib can be increased when combined with Rilonacept. |
| Rilpivirine | The serum concentration of Rilpivirine can be increased when it is combined with Idelalisib. |
| Rimegepant | The serum concentration of Rimegepant can be increased when it is combined with Idelalisib. |
| Riociguat | The serum concentration of Idelalisib can be increased when it is combined with Riociguat. |
| Ripretinib | Ripretinib may decrease the excretion rate of Idelalisib which could result in a higher serum level. |
| Risankizumab | The risk or severity of adverse effects can be increased when Idelalisib is combined with Risankizumab. |
| Ritonavir | The serum concentration of Idelalisib can be increased when it is combined with Ritonavir. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Idelalisib. |
| Rivaroxaban | The serum concentration of Idelalisib can be increased when it is combined with Rivaroxaban. |
| Rofecoxib | The metabolism of Idelalisib can be increased when combined with Rofecoxib. |
| Roflumilast | The serum concentration of Roflumilast can be increased when it is combined with Idelalisib. |
| Rolapitant | Rolapitant may decrease the excretion rate of Idelalisib which could result in a higher serum level. |
| Romidepsin | The metabolism of Romidepsin can be decreased when combined with Idelalisib. |
| Ropeginterferon a | The risk or severity of adverse effects can be increased when Idelalisib is combined with Ropeginterferon alfa-2b. |
| Ropivacaine | The risk or severity of methemoglobinemia can be increased when Idelalisib is combined with Ropivacaine. |
| Rosuvastatin | The metabolism of Idelalisib can be decreased when combined with Rosuvastatin. |
| Rotavirus vaccine | The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Idelalisib. |
| Roxadustat | The serum concentration of Idelalisib can be increased when it is combined with Roxadustat. |
| Roxithromycin | The metabolism of Idelalisib can be decreased when combined with Roxithromycin. |
| Rubella virus vacc | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Idelalisib. |
| Rucaparib | The metabolism of Idelalisib can be decreased when combined with Rucaparib. |
| Rufinamide | The metabolism of Idelalisib can be increased when combined with Rufinamide. |
| Ruxolitinib | The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Idelalisib. |
| Safinamide | Safinamide may decrease the excretion rate of Idelalisib which could result in a higher serum level. |
| Sapropterin | The serum concentration of Idelalisib can be increased when it is combined with Sapropterin. |
| Saquinavir | The metabolism of Idelalisib can be decreased when combined with Saquinavir. |
| Sarecycline | The serum concentration of Idelalisib can be increased when it is combined with Sarecycline. |
| Sarilumab | The metabolism of Idelalisib can be increased when combined with Sarilumab. |
| Satralizumab | The serum concentration of Idelalisib can be decreased when it is combined with Satralizumab. |
| Secobarbital | The metabolism of Idelalisib can be increased when combined with Secobarbital. |
| Secukinumab | The metabolism of Idelalisib can be increased when combined with Secukinumab. |
| Selexipag | The serum concentration of Selexipag can be increased when it is combined with Idelalisib. |
| Selpercatinib | The serum concentration of Selpercatinib can be increased when it is combined with Idelalisib. |
| Selumetinib | The serum concentration of Selumetinib can be increased when it is combined with Idelalisib. |
| Sildenafil | The serum concentration of Idelalisib can be increased when it is combined with Sildenafil. |
| Silodosin | The serum concentration of Idelalisib can be increased when it is combined with Silodosin. |
| Siltuximab | The metabolism of Idelalisib can be increased when combined with Siltuximab. |
| Simeprevir | The metabolism of Idelalisib can be decreased when combined with Simeprevir. |
| Simvastatin | The serum concentration of Idelalisib can be increased when it is combined with Simvastatin. |
| Sincalide | The excretion of Sincalide can be decreased when combined with Idelalisib. |
| Siponimod | The risk or severity of adverse effects can be increased when Idelalisib is combined with Siponimod. |
| Sipuleucel-T | The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Idelalisib. |
| Sirolimus | The risk or severity of adverse effects can be increased when Sirolimus is combined with Idelalisib. |
| Sitagliptin | The serum concentration of Idelalisib can be increased when it is combined with Sitagliptin. |
| Sitaxentan | The metabolism of Idelalisib can be decreased when combined with Sitaxentan. |
| Smallpox | The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Idelalisib. |
| Sofosbuvir | The serum concentration of Idelalisib can be increased when it is combined with Sofosbuvir. |
| Somatostatin | The metabolism of Idelalisib can be decreased when combined with Somatostatin. |
| Somatrogon | The metabolism of Idelalisib can be increased when combined with Somatrogon. |
| Sonidegib | The metabolism of Sonidegib can be decreased when combined with Idelalisib. |
| Sorafenib | The risk or severity of adverse effects can be increased when Sorafenib is combined with Idelalisib. |
| Sotagliflozin | Sotagliflozin may decrease the excretion rate of Idelalisib which could result in a higher serum level. |
| Sotorasib | The serum concentration of Idelalisib can be decreased when it is combined with Sotorasib. |
| Spesolimab | The risk or severity of adverse effects can be increased when Idelalisib is combined with Spesolimab. |
| St. John’s Wort | The metabolism of Idelalisib can be increased when combined with St. John’s Wort. |
| Stiripentol | The metabolism of Idelalisib can be decreased when combined with Stiripentol. |
| Streptozocin | The risk or severity of adverse effects can be increased when Streptozocin is combined with Idelalisib. |
| Sulfamethoxazole | The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Idelalisib. |
| Sulfasalazine | The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Idelalisib. |
| Sulfinpyrazone | The metabolism of Idelalisib can be increased when combined with Sulfinpyrazone. |
| Sumatriptan | The excretion of Sumatriptan can be decreased when combined with Idelalisib. |
| Sunitinib | The risk or severity of adverse effects can be increased when Sunitinib is combined with Idelalisib. |
| Suvorexant | The metabolism of Idelalisib can be decreased when combined with Suvorexant. |
| Tacrolimus | The serum concentration of Tacrolimus can be increased when it is combined with Idelalisib. |
| Tafamidis | The serum concentration of Idelalisib can be increased when it is combined with Tafamidis. |
| Talazoparib | The serum concentration of Talazoparib can be increased when it is combined with Idelalisib. |
| Tamoxifen | The metabolism of Idelalisib can be increased when combined with Tamoxifen. |
| Tasimelteon | The metabolism of Idelalisib can be decreased when combined with Tasimelteon. |
| Taurocholic acid | Taurocholic acid may decrease the excretion rate of Idelalisib which could result in a higher serum level. |
| Tazemetostat | The metabolism of Idelalisib can be decreased when combined with Tazemetostat. |
| Technetium | The excretion of Technetium Tc-99m mebrofenin can be decreased when combined with Idelalisib. |
| Technetium | The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Idelalisib. |
| Tecovirimat | The metabolism of Idelalisib can be increased when combined with Tecovirimat. |
| Tegaserod | The serum concentration of Idelalisib can be increased when it is combined with Tegaserod. |
| Telaprevir | The metabolism of Idelalisib can be decreased when combined with Telaprevir. |
| Telithromycin | The metabolism of Idelalisib can be decreased when combined with Telithromycin. |
| Telmisartan | Telmisartan may decrease the excretion rate of Idelalisib which could result in a higher serum level. |
| Telotristat ethyl | The serum concentration of Idelalisib can be decreased when it is combined with Telotristat ethyl. |
| Temozolomide | The risk or severity of adverse effects can be increased when Temozolomide is combined with Idelalisib. |
| Temsirolimus | The risk or severity of adverse effects can be increased when Temsirolimus is combined with Idelalisib. |
| Teniposide | The metabolism of Idelalisib can be decreased when combined with Teniposide. |
| Tenofovir alafe | The metabolism of Idelalisib can be decreased when combined with Tenofovir alafenamide. |
| Tenofovir diso | The serum concentration of Idelalisib can be increased when it is combined with Tenofovir disoproxil. |
| Tepotinib | The serum concentration of Idelalisib can be increased when it is combined with Tepotinib. |
| Teprotumumab | The risk or severity of adverse effects can be increased when Teprotumumab is combined with Idelalisib. |
| Terbinafine | The metabolism of Idelalisib can be increased when combined with Terbinafine. |
| Terfenadine | The metabolism of Idelalisib can be decreased when combined with Terfenadine. |
| Teriflunomide | The risk or severity of adverse effects can be increased when Teriflunomide is combined with Idelalisib. |
| Testosterone | The metabolism of Idelalisib can be increased when combined with Testosterone. |
| Tetracaine | The risk or severity of methemoglobinemia can be increased when Idelalisib is combined with Tetracaine. |
| Tetracycline | The metabolism of Idelalisib can be decreased when combined with Tetracycline. |
| Tezacaftor | The serum concentration of Tezacaftor can be increased when it is combined with Idelalisib. |
| Thalidomide | The risk or severity of adverse effects can be increased when Thalidomide is combined with Idelalisib. |
| Theophylline | The metabolism of Theophylline can be decreased when combined with Idelalisib. |
| Thiamylal | The metabolism of Idelalisib can be increased when combined with Thiamylal. |
| Thiotepa | The risk or severity of adverse effects can be increased when Thiotepa is combined with Idelalisib. |
| Ticagrelor | The metabolism of Idelalisib can be decreased when combined with Ticagrelor. |
| Tick-borne | The therapeutic efficacy of Tick-borne encephalitis vaccine (whole virus, inactivated) can be decreased when used in combination with Idelalisib. |
| Tioguanine | The risk or severity of adverse effects can be increased when Tioguanine is combined with Idelalisib. |
| Tipranavir | The metabolism of Idelalisib can be decreased when combined with Tipranavir. |
| Tivozanib | Tivozanib may decrease the excretion rate of Idelalisib which could result in a higher serum level. |
| Tixocortol | The risk or severity of adverse effects can be increased when Idelalisib is combined with Tixocortol. |
| Tocilizumab | The metabolism of Idelalisib can be increased when combined with Tocilizumab. |
| Tofacitinib | The metabolism of Tofacitinib can be decreased when combined with Idelalisib. |
| Tolvaptan | The metabolism of Tolvaptan can be decreased when combined with Idelalisib. |
| Topiramate | The metabolism of Idelalisib can be increased when combined with Topiramate. |
| Topotecan | The risk or severity of adverse effects can be increased when Topotecan is combined with Idelalisib. |
| Torasemide | The excretion of Torasemide can be decreased when combined with Idelalisib. |
| Toremifene | The serum concentration of Idelalisib can be increased when it is combined with Toremifene. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Idelalisib. |
| Trabectedin | The risk or severity of adverse effects can be increased when Trabectedin is combined with Idelalisib. |
| Tramadol | The metabolism of Tramadol can be decreased when combined with Idelalisib. |
| Trastuzumab | Trastuzumab may increase the neutropenic activities of Idelalisib. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Idelalisib. |
| Tretinoin | The risk or severity of adverse effects can be increased when Tretinoin is combined with Idelalisib. |
| Triamcinolone | The metabolism of Idelalisib can be increased when combined with Triamcinolone. |
| Triclabendazole | The metabolism of Idelalisib can be decreased when combined with Triclabendazole. |
| Trifluoperazine | The metabolism of Trifluoperazine can be decreased when combined with Idelalisib. |
| Trifluridine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Idelalisib. |
| Trilaciclib | The serum concentration of Trilaciclib can be increased when it is combined with Idelalisib. |
| Trilostane | The risk or severity of adverse effects can be increased when Trilostane is combined with Idelalisib. |
| Trimipramine | The serum concentration of Trimipramine can be increased when it is combined with Idelalisib. |
| Troglitazone | The metabolism of Idelalisib can be increased when combined with Troglitazone. |
| Troleandomycin | The metabolism of Idelalisib can be decreased when combined with Troleandomycin. |
| Tucatinib | Tucatinib may decrease the excretion rate of Idelalisib which could result in a higher serum level. |
| Typhoid vaccine | The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Idelalisib. |
| Typhoid Va | The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Idelalisib. |
| Typhoid Vi | The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Idelalisib. |
| Ubrogepant | The serum concentration of Ubrogepant can be increased when it is combined with Idelalisib. |
| Umbralisib | The serum concentration of Idelalisib can be increased when it is combined with Umbralisib. |
| Umeclidinium | The serum concentration of Umeclidinium can be increased when it is combined with Idelalisib. |
| Upadacitinib | The risk or severity of adverse effects can be increased when Idelalisib is combined with Upadacitinib. |
| Valoctocogene | The therapeutic efficacy of Valoctocogene roxaparvovec can be decreased when used in combination with Idelalisib. |
| Valproic acid | The metabolism of Idelalisib can be decreased when combined with Valproic acid. |
| Valsartan | The excretion of Valsartan can be decreased when combined with Idelalisib. |
| Vandetanib | The metabolism of Vandetanib can be decreased when combined with Idelalisib. |
| Vardenafil | The metabolism of Vardenafil can be decreased when combined with Idelalisib. |
| Varicella zoster | The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Idelalisib. |
| Varicella zoster | The therapeutic efficacy of Varicella zoster vaccine (recombinant) can be decreased when used in combination with Idelalisib. |
| Vedolizumab | The risk or severity of adverse effects can be increased when Vedolizumab is combined with Idelalisib. |
| Velpatasvir | Velpatasvir may decrease the excretion rate of Idelalisib which could result in a higher serum level. |
| Vemurafenib | The serum concentration of Idelalisib can be increased when it is combined with Vemurafenib. |
| Venetoclax | The metabolism of Idelalisib can be decreased when combined with Venetoclax. |
| Venlafaxine | Venlafaxine may increase the excretion rate of Idelalisib which could result in a lower serum level and potentially a reduction in efficacy. |
| Verapamil | The metabolism of Idelalisib can be decreased when combined with Verapamil. |
| Vibrioantigen | The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Idelalisib. |
| Vilanterol | The risk or severity of adverse effects can be increased when Idelalisib is combined with Vilanterol. |
| Viloxazine | The metabolism of Idelalisib can be decreased when combined with Viloxazine. |
| Vinblastine | The metabolism of Idelalisib can be increased when combined with Vinblastine. |
| Vincristine | The risk or severity of adverse effects can be increased when Vincristine is combined with Idelalisib. |
| Vindesine | The risk or severity of adverse effects can be increased when Vindesine is combined with Idelalisib. |
| Vinflunine | The metabolism of Vinflunine can be decreased when combined with Idelalisib. |
| Vinorelbine | The risk or severity of adverse effects can be increased when Vinorelbine is combined with Idelalisib. |
| Vismodegib | Vismodegib may decrease the excretion rate of Idelalisib which could result in a higher serum level. |
| Vitamin E | The metabolism of Idelalisib can be increased when combined with Vitamin E. |
| Voclosporin | The risk or severity of adverse effects can be increased when Idelalisib is combined with Voclosporin. |
| Vorapaxar | The metabolism of Idelalisib can be decreased when combined with Vorapaxar. |
| Voriconazole | The metabolism of Idelalisib can be decreased when combined with Voriconazole. |
| Vorinostat | The risk or severity of adverse effects can be increased when Vorinostat is combined with Idelalisib. |
| Voxelotor | The serum concentration of Idelalisib can be increased when it is combined with Voxelotor. |
| Voxilaprevir | Voxilaprevir may decrease the excretion rate of Idelalisib which could result in a higher serum level. |
| Warfarin | The serum concentration of Warfarin can be increased when it is combined with Idelalisib. |
| Yellow fever vaccine | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Idelalisib. |
| Zafirlukast | The metabolism of Idelalisib can be decreased when combined with Zafirlukast. |
| Zanubrutinib | The metabolism of Zanubrutinib can be decreased when combined with Idelalisib. |
| Zidovudine | The risk or severity of adverse effects can be increased when Zidovudine is combined with Idelalisib. |
| Zimelidine | The metabolism of Idelalisib can be decreased when combined with Zimelidine. |
| Ziprasidone | The metabolism of Idelalisib can be decreased when combined with Ziprasidone. |
| Zonisamide | The serum concentration of Idelalisib can be increased when it is combined with Zonisamide. |
| Zopiclone | The metabolism of Zopiclone can be decreased when combined with Idelalisib. |
| Zuclopenthixol | The metabolism of Idelalisib can be decreased when combined with Zuclopenthixol. |
Pregnancy and Lactation
FDA Pregnancy Category D
Pregnancy
Based on findings in animals, Zydelig may cause fetal harm when administered to a pregnant woman. Idelalisib was teratogenic in animals. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus.
Lactation
No information is available on the clinical use of idelalisib during breastfeeding. Because idelalisib is more than 84% bound to plasma proteins, the amount in milk is likely to be low. It is sometimes given in combination with rituximab, which may increase the risk to the infant. The manufacturer recommends that breastfeeding be discontinued during idelalisib therapy and for at least 1 month after the last dose.
How should this medicine be used?
Idelalisib comes as a tablet to take by mouth. It is usually taken with or without food twice a day. Take idelalisib at around the same times every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take idelalisib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.
Swallow the tablets whole; do not split, chew, or crush them.
Your doctor may decrease your dose of idelalisib or tell you to stop taking the medication for a time or permanently if you experience serious side effects during your treatment. This depends on how well the medication works for you and the side effects you experience. Talk to your doctor about how you are feeling during your treatment. Continue to take idelalisib even if you feel well. Do not stop taking idelalisib without talking to your doctor. Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient.
What special precautions should I follow?
Before taking idelalisib,
- tell your doctor and pharmacist if you are allergic to idelalisib, any other medications, or any of the ingredients in idelalisib tablets. If you have ever had a severe allergic reaction in the past, such as swelling of your face, lips or throat; difficulty swallowing or breathing; or peeling, blistering skin, your doctor will probably tell you not to take idelalisib.Ask your pharmacist or check the Medication Guide for a list of the ingredients.
- tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: carbamazepine (Carbatrol, Epitol, Equetro, others); clarithromycin (Biaxin, in PrevPac); itraconazole (Onmel, Sporanox); ketoconazole (Nizoral); medications used to treat human immunodeficiency virus (HIV) such as efavirenz (Sustiva, in Atripla), indinavir (Crixivan), nelfinavir (Viracept), nevirapine (Viramune), ritonavir (Norvir, in Kaletra, in Technivie); midazolam; nefazodone; phenobarbital; phenytoin (Dilantin, Phenytek); pioglitazone (Actos, in Actoplus Met, in Duetact, in Oseni); rifabutin (Mycobutin); and rifampin (Rifadin, Rimactane, in Rifamate, in Rifater). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with idelalisib, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.
- tell your doctor and pharmacist what herbal products you are taking, especially St. John’s wort. You should not take St. John’s wort during your treatment with idelalisib.
- tell your doctor if you are pregnant, plan to become pregnant, or plan to father a child. You should not become pregnant during your treatment with idelalisib. You should use birth control to prevent pregnancy during your treatment with idelalisib and at least 1 month after your final dose. If you are a male and your partner can become pregnant, you should use effective birth control during your treatment and for 3 months after your final dose. If you or your partner become pregnant while taking idelalisib, call your doctor immediately. Idelalisib may harm the fetus.
- tell your doctor if you are breastfeeding. You should not breastfeed while you are taking idelalisib and for at least one month after your final dose.
